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Abstract
Currently, there is much interest in identifying
clinically relevant biomarkers, as they have the
potential to be high utility non-invasive tools for early
diagnosis and reliable patient monitoring in
numerous conditions. Since its discovery almost 15
years ago, research on the ubiquitous antioxidant
enzyme peroxiredoxin 4 (Prx4) has culminated in the
recognition that Prx4 levels are different in blood
drawn from the healthy general population and
patients with acute or chronic diseases. In this
commentary, the most striking research data from
different in vitro approaches, animal models and
human observational studies are discussed
collectively, highlighting the clinical importance of
Prx4 as a multifunctional staging and prognosis
biomarker. In this context, the oxidative state of
patients may be reflected by intra- and extracellular
Prx4 levels, redox state, oligomerization and nitro-
oxidative modifications of the enzyme. A consolidated
model of the potential role and origin of circulating
Prx4 is presented to stimulate further investigations in
light of the current biomarker situation.
Background
Physiologically important processes such as redox sig-
naling and host defense depend on balanced amounts of
reactive oxygen species (ROS), including free radicals
and stable oxidizing molecules, for example, hydrogen
peroxide (H2O2). In conditions of oxidative stress,
increased ROS levels overwhelm antioxidant protection
mechanisms, resulting in the development and progres-
sion of various diseases [1].
Peroxiredoxin 4 (Prx4; synonyms: AOE372, TRANK)
is a ubiquitously expressed member of the peroxiredoxin
family that is localized in the endoplasmic reticulum
(ER) and extracellular space [2,3], with highest expres-
sion in the pancreas, liver and heart, and lowest expres-
sion in blood leukocytes and the brain [2,4]. The
enzyme diminishes oxidative stress by reducing hydro-
gen peroxide to water in a thiol-dependent catalytic
cycle [5] and has been linked to the regulation of the
key pro-inflammatory transcription factor, nuclear factor
kappa B (NF-B) [2,4,6]. In addition, redox-dependent
and reversible conversion of homologous Prx1-4 from
disulfide-linked homodimers to higher-order multimers
and back provides a versatile mechanism to switch
between peroxidase and chaperone activity, enabling
interaction with binding partners including stress-
responsive kinases, membrane proteins and immune-
modulators, fine-tuning of H2O2 signaling [7] and, as
published most recently, circadian clock oscillations [8].
Disturbances in the aforementioned fundamental pro-
cesses clearly result in numerous pathological conditions
that could potentially be reflected by the measurement
of involved Prx.
Among the six Prx isoforms in mammals, Prx4
emerges as the most attractive, easily accessible biomar-
ker candidate as it was initially designated as a secreta-
ble peroxidase [2,9], has recently been identified in the
circulation of healthy and diseased individuals [10,11]
and, finally, has been linked to morbidity and mortality
in patients with sepsis in the intensive care unit and
patients with non-specific complaints in the emergency
department [12,13]. In addition, several studies have
shown that the expression or oxidation state of Prx4
changes under pathological conditions such as cancer
[14-20], diabetes [21-23] and infection [4,6,24-27].
Fast evolving genomic and proteomic studies con-
stantly provide many new biomarker candidates, una-
voidably lacking a differentiated evaluation of single
candidates and possibly misdirecting promising fields of
application. Hence, this commentary intends to discuss
the available data on Prx4 at an early stage, focusing on
the relevant clinical evidence that indicates strong
Correspondence: janin.schulte@thermofisher.com
Department of Research and Development, BRAHMS GmbH, Part of Thermo
Fisher Scientific, 16761 Hennigsdorf, Germany
Schulte BMC Medicine 2011, 9:137
http://www.biomedcentral.com/1741-7015/9/137
© 2011 Schulte; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.biomarker potential in a number of conditions in critical
care and the emergency room.
Discussion
Clinical significance of Prx4 detection
Prx4 should be of special interest to clinicians as it may
represent a new marker candidate that could be highly
valuable in predicting the prognosis of an adverse out-
come to risk stratify patients and to monitor therapy.
Indeed, serum and expression levels, as well as post-
translational modifications, of the enzyme have been
linked to a number of different diseases, ranging from
primary care to advanced critical care topics (see Addi-
tional file 1). The biomarker performance of Prx4 in
these patients is truly encouraging, given the high het-
erogeneity and potential confounders, such as co-mor-
bidities and medication. Indeed, Prx4 expression in the
mouse liver was responsive to different drugs, including
the analgesic paracetamol and the chemotherapeutic
etoposide phosphate [28]. Altogether, Prx4 is assumed
to be important in many single settings, which is very
promising, but requires further validation. The results
found by Chang and colleagues [10], for instance, are
methodologically questionable because they are based
on an immunoassay that worked with diluted patient
plasma directly coated to the solid phase, which strongly
limits specific antibody binding. Moreover, findings
from different cancer studies are in part contradictory,
concluding either good [16,18] or bad prognosis [14,19]
from increased Prx4 expression in tumor tissue. Specifi-
cally, sepsis [29], cancer [30] and cardiovascular disease
[31] are candidate diseases where Prx4 measurement
may be of particular use as they share redox and inflam-
matory dysregulation and frequently lack valid severity
and risk assessment by non-invasive biomarkers.
Perspectives for Prx4 testing methods
An improved understanding of the redox regulation,
structural assembly and activity of Prx4 would provide a
better insight into analyzing Prx4 as a biomarker in tis-
sue or serum. Conoidin A, a specific Prx activity inhibi-
tor, is currently under evaluation [32]. Tavender and
Bulleid found Prx4 oxidation to be indicative of the
degree of oxidative stress in the ER [3]. Atherosclerotic
plaque development (Full et al., unpublished data), viral
infection of A549 lung adenocarcinoma epithelial cells
[25] and stimulation of human umbilical vein endothe-
lial cells (HUVEC) with H2O2 and hydroperoxides [33]
resulted in oxidation and a shifted isoelectric point of
Prx4, respectively. Moreover, selective changes for either
a putative 31-kDa precursor or 27-kDa secretable Prx4
have been reported in lung cancer [34] and spermato-
genesis disorders [35,36]. Consequently, detection of
Prx4 hyperoxidation and oligomerization [3,25,37,38]
could be a meaningful, albeit challenging, measure of
thiol-redox imbalances and should be integrated into
Prx4 analysis. Existing expression data, however, require
careful interpretation in light of a newly discovered
29.5-kDa splice variant of Prx4 [39] that cannot be
recognized by the antibodies used in the immunoassay
that has been developed for the detection of Prx4
dimers and oligomers in serum [11].
Origin and drivers of circulating Prx4
The amount of secreted Prx4 is most likely proportional
to the initial intracellular expression levels. With excep-
tions [40], it has been shown in different in vivo models
of infection that Prx4 expression was further potentiated
in organs with strong endogenous expression of the
enzyme [26,41]. Consequently, tissue with high basal or
up-regulated cellular expression of Prx4 likely represents
a source for circulating Prx4 (Figure 1). Okado-Matsu-
moto and colleagues hypothesized that the enzyme is
bound to the endothelial cells of blood vessels and
released in response to a changed redox environment
[9], matched by the high expression of Prx4 in endothe-
lial cells [2]. There is sufficient further evidence that
augmented Prx4 serum levels may be a result of secre-
tion in response to pro-oxidant and pro-inflammatory
signaling cascades, possibly related to regulation of NF-
B [2,4,6] (Figure 1). Indeed, Prx4 serum levels are cor-
related with endogenous antioxidants (albumin, biliru-
bin) and markers of inflammation (C-reactive protein,
interleukin-6) in critically ill patients [13]. Moreover,
changes in Prx4 expression or oxidation resulted from
viral infection [4,6,24-27] ando x i d a t i v es t i m u l a t i o n
[33,38,42,43]in vitro and in vivo. Preliminary data from
Madin-Darby canine kidney strain I cells stably trans-
fected with Prx4 revealed a significant dose-dependent
increase of Prx4 secretion after stimulation with H2O2
(Schulte et al., unpublished data). In addition, intracellu-
lar Prx4 was associated with nitrotyrosine expression in
bladder and ovarian cancer [14,16,44] and nitric oxide-
dependent regulation in stimulated macrophages [43],
suggesting nitrosative stress as another promoter of
Prx4 secretion. Ultimately, circulating Prx4 may origi-
nate from non-specific membrane leakage due to tissue
damage and apoptotic cell death, representing a conse-
quence of the aforementioned stress stimuli (Figure 1).
Consequences of Prx4 modification
Intracellular Prx4 is mainly localized in the ER, where it
contributes to redox and disulfide regulation [3],
whereas no definite function has yet been assigned for
extracellular Prx4 [6,9]. Preincubation of HUVEC with
reduced Prx4 resulted in improved cell viability after
H2O2 treatment [9]. Protective anti-inflammatory effects
have been reported for Prx4, when injected or
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expression has been shown to be relevant for the antiox-
idant effects of natural compounds [42,45,46]. Chaper-
one activity in the extracellular space is conceivable, but
requires experimental confirmation [7,47]. A recent pub-
lication by Palande and colleagues indirectly linked Prx4
to the innate immune system by showing that ER-loca-
lized Prx4 has an inhibitory effect on granulocyte col-
ony-stimulating factor, which is a key regulator of
neutrophil production [48]. However, Prx4 secretion
could lead to a loss of intracellular or membrane-bound
Prx4, which would result in a changed capacity to
remove H2O2, to regulate redox mechanisms or to parti-
cipate in signaling pathways in the cellular vicinity. The
resulting cellular oxidative stress and disturbed signaling
would initiate and exacerbate pathological processes, lar-
gely increasing the probability of adverse outcome and
death. On this basis, a speculative model is suggested,
concluding that increased serum levels of Prx4 as a
result of unfavorable Prx4 translocation could indicate
higher morbidity (Figure 2). Indeed, elevated Prx4
serum levels have been linked to adverse outcome and
higher mortality in critical care and emergency settings
[12,13] as well as in the general population (Abbasi et
al., unpublished data) and type 2 diabetes mellitus
patients (Alkhalaf et al., unpublished data). In addition,
elevated intracellular Prx4 levels in carcinoma tissue are
associated with improved survival [16,18], in contrast to
the fact that tumor cells escape apoptosis by increased
Prx4 expression [49-52]. This is in better agreement
with results from other settings reporting higher mortal-
ity in cancer patients with increased Prx4 expression
levels in tumor tissue [14,19]. Finally, there is evidence
that Prx isoforms and other antioxidants can substitute
for Prx4 [14,18,25,34,53], resulting in compensation for
functional consequences of Prx4 release.
Conclusions
It seems reasonable by now to expand basic clinical
research from exclusive expression studies to mechan-
isms of Prx4 release, oligomerization and oxidative mod-
ification in order to identify relevant biochemical
interrelations and refine the actual biomarker value of
Prx4. Present data indicate that Prx4, either intracellular
or extracellular, has the potential to serve as a biomar-
ker for both the early staging of disease severity and the
prediction of the future disease course in different
pathologies that involve dysregulation of the redox sys-
tem, for example, as evident during inflammatory pro-
cesses. Accordingly, it is recommended that promising
results from recent studies be validated and clinical
trials be performed in new indications to ultimately
Figure 1 Potential origin and regulation of peroxiredoxin 4. Peroxiredoxin 4 (Prx4) is known to switch between dimer and pentadimeric
decamer structure [3], with potential decameric structure having been identified in circulation [11]. It has been shown that Prx4 redox-
dependently binds to the cell surface of human umbilical vein endothelial cells [9]. Specific and non-specific stimulation of various tissues has
influenced Prx4 expression, oxidation or oligomerization and may ultimately result in secretion of Prx4. H2O2: hydrogen peroxide; LPS:
lipopolysaccharide; NaDOC: sodium deoxycholate; NF-B: nuclear factor-kappa B; NO: nitric oxide; Prx4: peroxiredoxin 4; RNS: reactive nitrogen
species; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand.
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therapy monitoring in comparison with existing
standards.
Additional material
Additional file 1: Peroxiredoxin 4 in clinical indications. This
overview does not presume to be complete. Indeed, cited cancer
settings are limited to subgroups with important clinical findings beyond
changes in peroxiredoxin 4 expression. Unless otherwise mentioned, the
term ‘Prx4’ refers to intracellular protein levels.
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